Credit Suisse’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.99M | Buy |
51,278
+1,410
| +3% | +$49.3K | ﹤0.01% | 1863 |
|
|
2023
Q4 | $1.53M | Buy |
49,868
+1,788
| +4% | +$44.8K | ﹤0.01% | 2060 |
|
|
2023
Q3 | $1.07M | Buy |
48,080
+7,252
| +18% | +$165K | ﹤0.01% | 2252 |
|
|
2023
Q2 | $877K | Buy |
40,828
+1,309
| +3% | +$29.7K | ﹤0.01% | 2470 |
|
|
2023
Q1 | $948K | Buy |
39,519
+3,028
| +8% | +$80.3K | ﹤0.01% | 2363 |
|
|
2022
Q4 | $847K | Buy |
36,491
+10,997
| +43% | +$222K | ﹤0.01% | 2457 |
|
|
2022
Q3 | $408K | Buy |
25,494
+197
| +0.8% | +$3.47K | ﹤0.01% | 2910 |
|
|
2022
Q2 | $448K | Buy |
25,297
+12
| +0% | +$202 | ﹤0.01% | 2913 |
|
|
2022
Q1 | $515K | Buy |
25,285
+1,671
| +7% | +$31.6K | ﹤0.01% | 2954 |
|
|
2021
Q4 | $441K | Buy |
23,614
+1,584
| +7% | +$30.9K | ﹤0.01% | 3909 |
|
|
2021
Q3 | $435K | Sell |
22,030
-5,199
| -19% | -$112K | ﹤0.01% | 3895 |
|
|
2021
Q2 | $644K | Buy |
27,229
+172
| +0.6% | +$3.97K | ﹤0.01% | 3675 |
|
|
2021
Q1 | $641K | Sell |
27,057
-10,387
| -28% | -$247K | ﹤0.01% | 3603 |
|
|
2020
Q4 | $751K | Buy |
37,444
+12,757
| +52% | +$249K | ﹤0.01% | 3550 |
|
|
2020
Q3 | $513K | Buy |
24,687
+2,108
| +9% | +$38K | ﹤0.01% | 3380 |
|
|
2020
Q2 | $395K | Sell |
22,579
-5,481
| -20% | -$107K | ﹤0.01% | 3452 |
|
|
2020
Q1 | $458K | Sell |
28,060
-13,841
| -33% | -$286K | ﹤0.01% | 3169 |
|
|
2019
Q4 | $863K | Buy |
41,901
+14,847
| +55% | +$247K | ﹤0.01% | 3237 |
|
|
2019
Q3 | $311K | Sell |
27,054
-28,242
| -51% | -$322K | ﹤0.01% | 3677 |
|
|
2019
Q2 | $727K | Buy |
55,296
+27,731
| +101% | +$371K | ﹤0.01% | 3167 |
|
|
2019
Q1 | $418K | Buy |
27,565
+1,632
| +6% | +$26.1K | ﹤0.01% | 3434 |
|
|
2018
Q4 | $445K | Buy |
25,933
+5,029
| +24% | +$86K | ﹤0.01% | 3316 |
|
|
2018
Q3 | $308K | Sell |
20,904
-8,560
| -29% | -$152K | ﹤0.01% | 3511 |
|
|
2018
Q2 | $703K | Sell |
29,464
-46,620
| -61% | -$1.15M | ﹤0.01% | 3251 |
|
|
2018
Q1 | $1.94M | Buy |
76,084
+47,000
| +162% | +$1.12M | ﹤0.01% | 2449 |
|
|
2017
Q4 | $536K | Buy |
29,084
+10,652
| +58% | +$153K | ﹤0.01% | 3400 |
|
|
2017
Q3 | $193K | Buy |
+18,432
| New | +$203K | ﹤0.01% | 3939 |
|
|
2017
Q2 | – | Sell |
-13,630
| Closed | -$137K | – | 3838 |
|
|
2017
Q1 | $137K | Buy |
13,630
+1,173
| +9% | +$17.4K | ﹤0.01% | 3672 |
|
|
2016
Q4 | $194K | Buy |
12,457
+610
| +5% | +$10.1K | ﹤0.01% | 3823 |
|
|
2016
Q3 | $228K | Sell |
11,847
-15,643
| -57% | -$186K | ﹤0.01% | 3766 |
|
|
2016
Q2 | $326K | Buy |
+27,490
| New | +$454K | ﹤0.01% | 3657 |
|
Other funds holding COLL
EAM
RCMNY
Credit Suisse's COLL Position: Q1 2024 in Review
Credit Suisse increased its Collegium Pharmaceutical (COLL) stake by 2.8% in Q1 2024, buying an estimated $49.3K and bringing the position to 51,278 shares worth $1.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1863.
Credit Suisse first reported a position in COLL in Q2 2016 and has held it in 31 quarters since. 228 funds tracked by Wall St. Rank hold COLL as of Q1 2024.
- Credit Suisse held 51,278 shares of Collegium Pharmaceutical worth $1.99M as of Q1 2024.
- Credit Suisse bought 1,410 Collegium Pharmaceutical shares in Q1 2024, an estimated $49.3K.
- Collegium Pharmaceutical made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1863 holding.
- Credit Suisse first reported a position in Collegium Pharmaceutical in Q2 2016 and has held it in 31 quarters since.
- 228 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.